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Background: Leptin is known to be elevated in pre-eclampsia/ pregnancy induced hypertension (PE/PIH). However
the reports on the association of leptin receptor (LEPR) c.668A>G polymorphism with PE/PIH are inconsistent.
Findings: LEPR c.668A>G polymorphism was studied in a cohort of women with PE/PIH (N = 61) and normotensive
pregnancies (N = 40) by polymerase chain reaction / restriction fragment length polymorphism. Genotype and allele
frequencies were in Hardy-Weinberg equilibrium within both groups (Chi square test). Allele and genotype
frequencies were not significantly different between PE/PIH and normotensive pregnancies (Chi square test). Leptin
levels (Kruskal Wallis analysis of variance) and leptin/body mass index (one way analysis of variance) were not
significantly different between genotypes within each group. However, leptin (Mann Whitney U test) and leptin
normalised to body mass index (unpaired t test) were significantly higher in PE/PIH women homozygous and
heterozygous for the G668 allele than in respective normotensives.
Conclusions: Whether the leptin receptor c.668A>G polymorphism increases the risk of developing PE/PIH in Sri
Lankan women remains inconclusive in view of the smaller sample studied. However leptin levels in PE/PIH
appeared to be modulated by this polymorphism.
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Background
Leptin, the first adipocyte hormone identified brings
about biological effects via its cognate receptor [1]. Lep-
tin receptor (LEPR) exists in several isoforms [2]. The
full length isoform as well as some isoforms with short
cytoplasmic domains are implicated in signal transduc-
tion [3-5]. LEPR isoform without the cytoplasmic and
transmembrane domains is shed from the cells and cir-
culates as the soluble leptin receptor. This modulates
biological availability of leptin [6]. Several single nucleo-
tide polymorphisms (SNPs) have also been identified in
LEPR [7]. Of the SNPs reported, c.668A>G polymorph-
ism in exon 6 (rs 1137101) has been reported to be* Correspondence: kamani@ibmbb.cmb.ac.lk
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distribution, and reproduction in any mediumassociated with body mass index, breast cancer and age
at menarche etc [8-10].
Pre-eclampsia / pregnancy induced hypertension (PE/
PIH) is a pregnancy complication with increased fetal
and maternal morbidity and mortality. It is thought to
arise due to abnormal placentation followed by a mater-
nal systemic disorder. Several studies including ours
have shown that PE/PIH is associated with elevated cir-
culating leptin levels and reduced levels of soluble leptin
receptor compared to normotensive pregnancies [11-14].
We previously demonstrated that a polymorphism in the
leptin gene increases risk of PE/PIH [14]. Studies on the
association of LEPR c.668A>G polymorphism with PE/
PIH are limited and findings have been inconsistent
[15,16]. There are no data on the possible association of
this polymorphism with PE/PIH for Sri Lanka or for any
other South Asian population to the best of our know-
ledge. Thus we examined the possible association oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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women with PE/PIH.
Results and discussion
There were 33 PE and 28 PIH patients in the PE/PIH
group. Genotype and allele distribution was not signifi-
cantly different between PE and PIH (Chi square test,
P = 0.969; P = 0.964 respectively). Therefore both PE and
PIH patients were analysed together. Both the PE/PIH
and control group were predominantly Sinhalese with
only 4 patients in the PE/PIH group and one subject in
the control group belonging to other ethnic groups (ie:
PE/PIH: 3 Muslims, 1 Tamil; control: 1 Muslim). Thus
ethnicity was not taken into account in the analysis.
Genotype and allele distributions in PE/PIH and nor-
mal pregnancy are shown in Table 1. Heterozygosity for
the LEPR c.668A>G polymorphism was the most com-
mon genotype in both groups. Genotype distributions
were in Hardy-Weinberg equilibrium within PE/PIH
(P = 0.752) and normotensive pregnancy (P = 0.710)
groups. Furthermore genotype frequencies did not sig-
nificantly differ between the two groups (P = 0.311).
Though the A668 allele was more frequent in PE/PIH
than in normal pregnancy, the difference was not statis-
tically significant (Chi square test: P = 0.372) and the
A668 allele did not confer a significantly higher risk of
developing PE/PIH [relative risk (95% confidence limits)
1.126 (0.899 to 1.408)].
Leptin levels and leptin normalized to body mass
index of PE/PIH subjects included in the present study
and some of the controls have been presented elsewhere
and we reported that both the leptin levels and leptin
normalized to body mass index were significantly higher
in PE/PIH [14]. Reanalysis by LEPR c.668A>G genotype
did not show any significant effect of the genotype on
leptin levels or leptin normalized to body mass index
(Table 2) within either group, though there was a ten-
dency for levels to increase from AA genotype to GG
genotype within the PE/PIH group. Leptin and leptin
normalized to body mass index remained significantlyTable 1 Genotype and allele frequencies in pre-eclampsia
/ pregnancy induced hypertension (PE/PIH) and normal
pregnancy
PE/PIH: N (%) Normal pregnancy: N (%) P value
Genotype
A668 homozygous 11 (18%) 06 (15%)
A668G heterozygous 42 (69%) 24 (60%) P = 0.311
G668 homozygous 08 (13%) 10 (25%)
Allele
A668 64 (52%) 36 (45%)
G668 58 (48%) 44 (55%) P = 0.372
P values are for the Chi square test comparing PE/PIH and normal pregnancy.higher in PE/PIH women who were heterozygous
(p = 0.0007, p = 0.0026 respectively) and homozygous for
the G668 allele (p = 0.0085, p = 0.0189 respectively) than
in the respective controls, but were not significantly dif-
ferent between PE/PIH and controls homozygous for the
A668 allele. Furthermore, BMI was significantly higher
in heterozygotes (p = 0.0093) in the PE/PIH group com-
pared to respective controls. BMI was higher in the
G668 homozygotes (p = 0.0616) in the PE/PIH group,
but this did not achieve a statistical significance.
Association of leptin and polymorphisms of the leptin
gene with increased risk of PE/PIH has been already well
documented [12-14]. However, there are only a very few
reports on the association of LEPR c.668A>G poly-
morphism with PE/PIH and these have remained incon-
sistent. A study from Hungary showed that the A668
allele was significantly associated with severe PE [15]
while no such association was observed in the HELLP
syndrome [17], perhaps signifying differences in the
underlying pathology. A recent study from Germany did
not find an association of LEPR c.668A>G polymorph-
ism with either PE or HELLP syndrome [16].
We previously demonstrated significantly higher
plasma leptin levels and free leptin index (leptin levels/
soluble leptin receptor levels) in women with PE/PIH
[14]. An increased risk of the disease was also conferred
by the A allele of −2548G/A polymorphism of the leptin
gene. In the present study LEPR c.668A>G polymorph-
ism of the same women with PE/PIH was studied. How-
ever, the prevalence of A and G alleles as well as
different genotypes was not significantly different be-
tween PE/PIH and normotensive pregnancies. Thus our
results contrast with those of Rigo et al [15], but support
recent findings of Wiedemann et al [16].
Some investigators have shown that G668 homozygosity
is associated with significantly higher levels of leptin when
compared to A668 homozygosity [18,19]. In a recent study
on a multiethnic cohort comprising of African, African-
American, African-Caribbean, Caucasian and Asian/other
ethnic groups this effect was observed only in Caucasians
[20]. In the present study leptin levels and leptin normal-
ized to BMI appeared to increase from A668 homozygos-
ity to G668 homozygosity with heterozygotes having
intermediate levels in PE/PIH. The differences did not
reach a statistical significance presumably due to the smal-
ler numbers in wild type and mutant homozygous groups.
Such an effect was not seen among the controls.
LEPR has two cytokine receptor homology domains
known as CRH1 and CRH2. c.668A>G polymorphism is
located in the CRH1 domain. It has been suggested that
CRH2 domain is adequate for signal transduction via
LEPR. When the functional significance of this poly-
morphism was studied using a mouse model it did not
show an effect on leptin signaling [21]. Our inability to
Table 2 Leptin levels (geometric mean and 95% confidence levels) and leptin normalized to body mass index (mean +
SD) in pre-eclampsia/ pregnancy induced hypertension (PE/PIH) and normal pregnancy by genotype
Genotype PE/PIH Normal pregnancy P value PE/PIH Normal pregnancy P Value
Leptin ng/mL Leptin ng/mL Leptin/BMI Leptin/BMI
A668 56.47 43.04 P= 0.1193 2.265+ 0.797 1.668+ 0.155 P = 0.0934
homozygous (43.55, 73.21) (34.91, 53.05)
A668G 62.51 42.41 P= 0.0007 2.334+ 0.772 1.775+ 0.527 P = 0.0026
heterozygous (56.48, 69.19) (34.79, 51.69)
G668 73.56 45.29 P= 0.0085 2.553+ 0.857 1.764+ 0.384 P = 0.0189
homozygous (58.45, 92.57) (35.27, 58.17)
P values are for Mann Whitney U test comparing PE/PIH with normal pregnancy.
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ism with PE/PIH in the present study may have resulted
from this lack of an effect on leptin signaling.
Increased maternal leptin in pregnancy is contributed
both from the placenta and the adipose tissue. Following
the delivery, maternal leptin levels return to pre-
pregnancy levels confirming that the placenta is the
major source of maternal leptin during pregnancy [22-
24]. Even when accounted for adipose tissue contribu-
tion by normalizing leptin levels to BMI, genotype asso-
ciated effect remained within the PE/PIH group
indicating that the LEPR c.668A>G polymorphism is
likely to modulate leptin levels in PE/PIH. A larger co-
hort of patients needs to be studied to confirm or refute
this finding as well as to examine the effect of LEPR
c.668A>G on the risk of PE/PIH in Sri Lankan women
as the present study is underpowered in view of the
smaller number of subjects studied.
Conclusions
Whether the leptin receptor c.668A>G polymorphism
increases the risk of developing PE/PIH in Sri Lankan
women thus remains inconclusive due to the limited
power of the present study. The effect of leptin receptor
c.668A>G polymorphism on the risk of developing PE/
PIH and whether LEPR c.668A>G polymorphism is
likely to significantly modulate leptin levels in PE/PIH
need to be studied using a larger cohort of patients.
Methods
Subjects
Sixty one women with PE/PIH were selected from those
who participated in a previous study on the association of
leptin with PE/PIH. Their characteristics have been
described in detail elsewhere [14]. Forty women with
normotensive pregnancies were included as controls. Of
these 19 subjects were selected from the control subjects
from our previous study on the basis of availability of
DNA aliquots. Remaining 21 subjects were recruited from
the same tertiary care hospital according to the previously
used study protocol. A sample size of 40 subjects in eachgroup has a 90% power at a significance level of 0.05 to
detect a 0.35 increase in the prevalence of G668 allele in
the test group assuming a prevalence 0.3 for the control
group. Ethical approval from the Research, Ethics and
Higher Degrees Committee of the Institute of Biochemis-
try, Molecular Biology and Biotechnology and written
informed consent from the study participants were
obtained prior to the study. Women in both groups had
naturally conceived singleton pregnancies. Exclusion cri-
teria were diabetes mellitus, gestational diabetes, chronic
hypertension, renal disease, polycystic ovarian syndrome,
menstrual cycle disturbances, previous history of infertil-
ity, as well as family history of diabetes mellitus or chronic
hypertension.
On admission to the study, maternal age, height, weight
and blood pressure were recorded and a sample of urine
tested for proteinuria. Criteria for diagnosing PE/PIH have
been described before [14]. Persistent (6 or more hours
apart) blood pressure of at least 140/90 mmHg arising
after 20 weeks of gestation was considered as PIH. Urine
protein concentration >300 mg/l or more (or 1+ on a
urine dipstick) in addition to hypertension was considered
as pre-eclampsia. A peripheral venous blood sample was
collected on diagnosis and before commencement of any
treatment from the PE/PIH patients and on admission to
the study in the third trimester from the controls.
Genomic DNA extracted from peripheral blood leuko-
cytes was used for amplification by polymerase chain re-
action (PCR) using exon specific primers. PCR products
were digested with Msp1 enzyme for restriction frag-
ment length polymorphism analysis by Agarose gel elec-
trophoresis [7].
Polymorphism at nucleotide position 668 from A>G
changes codon 223 from CAG [coding for glutamine
(Q)] to CGG [coding for Arginine (R)]. This change
results in an Msp 1 restriction site that cleaves the PCR
product on exposure to the enzyme. Gels were manually
scored as presence (G668 homozygosity), absence (A668
homozygosity) and heterozygosity of polymorphism.
RFLP results were further confirmed by repeat analysis
and by direct sequencing of representative samples. Chi-
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and allele distributions were in Hardy-Weinberg equilib-
rium within each group, as well as to test whether the al-
lele or genotype distributions differed between PE/PIH
and normotensive pregnancies.
Leptin levels and leptin normalized to body mass
index were compared between genotypes within each
group using Kruskall Wallis ANOVA and one way
ANOVA respectively. Leptin levels and leptin normal-
ized to body mass index between PE/PIH and controls
were compared after stratifying data by genotype using
Mann Whitney U test and unpaired Student’s t test
respectively.
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